Pfizer Inc (PFE) 29.95 $PFE
3 Dividend Stocks Better Than Pfizer, Inc.
Todd Campbell, The Motley Fool - Motley Fool - Sat Nov 01, 10:17AM CDT
Pfizer reported third-quarter earnings this week that were generally underwhelming. The drugmaker announced that its sales sagged 2.2% to $12.36 billion and its adjusted EPS fell similarly by 2% year over year in the quarter. Pfizer's...
NVO: 45.18 (-1.03), PFE: 29.95 (+0.11), AMGN: 162.18 (+0.60), NVS: 92.69 (+0.74)
Most active New York Stock Exchange-traded stocks
AP - Fri Oct 31, 5:04PM CDT
NEW YORK (AP) — A look at New York Stock Exchange 10 most-active stocks at the close of trading:
CCI: 78.12 (-5.12), F: 14.09 (+0.14), GE: 25.81 (+0.14), ABX.TO: 13.38 (-0.37), K.TO: 2.41 (-0.35), ABX: 11.87 (-0.42), C: 53.53 (+0.38), PFE: 29.95 (+0.11), BAC: 17.16 (+0.13), YRI.TO: 4.49 (-0.50), KGC: 2.15 (-0.34), S: 5.93 (-0.07), AUY: 3.98 (-0.48)
Final Glance: Pharmaceuticals companies
AP - Fri Oct 31, 5:04PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading:
JNJ: 107.78 (+0.74), BAX: 70.14 (+0.08), PFE: 29.95 (+0.11), BMY: 58.19 (-0.79)
Will Zoetis (ZTS) Pull a Surprise this Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 31, 4:10PM CDT
Zoetis Inc. (ZTS) is scheduled to report third-quarter 2014 results before the opening bell on Nov 4.
ZTS: 37.16 (-0.16), ACT: 242.74 (-0.47), PFE: 29.95 (+0.11), HSP: 53.70 (-0.54)
Midday Glance: Pharmaceuticals companies
AP - Fri Oct 31, 1:49PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:
JNJ: 107.78 (+0.74), BAX: 70.14 (+0.08), PFE: 29.95 (+0.11), BMY: 58.19 (-0.79)
Early Glance: Pharmaceuticals companies
AP - Fri Oct 31, 11:28AM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 10 a.m.:
JNJ: 107.78 (+0.74), BAX: 70.14 (+0.08), PFE: 29.95 (+0.11), BMY: 58.19 (-0.79)
Dow 30 Stock Roundup: DuPont, Merck, Pfizer Beat Estimates - Analyst Blog
Swarup Gupta - Zacks Investment Research - Fri Oct 31, 10:41AM CDT
The Dow experienced gains every day of the week, but for Wednesday, boosted by positive economic data and bullish earnings results.
MMM: 153.77 (+1.67), GS: 189.99 (+3.02), V: 241.43 (+4.78), IBM: 164.40 (+0.05), MRK: 57.94 (+0.63), PFE: 29.95 (+0.11), DD: 69.15 (+1.49), CAT: 101.41 (+1.25), PG: 87.27 (+0.33), MSFT: 46.95 (+0.90)
Stock Market News for October 31, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Fri Oct 31, 9:10AM CDT
Benchmarks ended in the green zone on Thursday, banking on encouraging third quarter GDP numbers and upbeat quarterly results
JNJ: 107.78 (+0.74), NEE: 100.22 (+0.31), V: 241.43 (+4.78), GILD: 112.00 (-2.22), DUK: 82.15 (-0.14), EXC: 36.59 (-0.11), MRK: 57.94 (+0.63), PFE: 29.95 (+0.11), ABBV: 63.46 (+2.28), DTE: 82.16 (+0.17), SO: 46.36 (-0.09), MA: 83.75 (+0.62)
Pfizer's Trumenba Gains Accelerated Approval in the U.S. - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Oct 30, 5:04PM CDT
Pfizer Inc.'s (PFE) Trumenba received accelerated FDA approval for prevention of invasive disease caused by Neisseria meningitidis serogroup B in people aged 10 - 25 years.
MNK: 92.18 (-0.65), ACT: 242.74 (-0.47), PFE: 29.95 (+0.11), MYL: 53.55 (+1.18)
'Mad Money' Lightning Round: Stay Away From Applied Materials
at The Street - Thu Oct 30, 5:00AM CDT
Cramer prefers Isis Pharmaceuticals to Pfizer and Kinder Morgan to El Paso Pipeline Partners.
KMI: 38.70 (+0.16), EPB: 40.65 (+0.10), ISIS: 46.06 (+0.18), PFE: 29.95 (+0.11), AMAT: 22.09 (+0.75), INVN: 16.21 (+0.54), IGT: 16.39 (+0.20), REGN: 393.72 (+0.92), CVRR: 24.24 (-0.10), CELG: 107.09 (+0.15)
Jim Cramer's 'Mad Money' Recap: Where to Find Bargains Created by the Fed
at The Street - Wed Oct 29, 7:12PM CDT
With the Federal Reserve finally ending its bond buying, there are many stocks that are ready to be bought, not sold, on any Fed-induced weakness, Cramer says.
KMI: 38.70 (+0.16), ETN: 68.39 (+1.62), FB: 74.99 (+0.88), PFE: 29.95 (+0.11), INVN: 16.21 (+0.54), WDC: 98.37 (+3.18), HPQ: 35.88 (+0.56), CVRR: 24.24 (-0.10), CELG: 107.09 (+0.15), EPB: 40.65 (+0.10), ISIS: 46.06 (+0.18), IBM: 164.40 (+0.05), AMAT: 22.09 (+0.75), GOOGL: 567.87 (+7.60), TWTR: 41.47 (-0.33), MSFT: 46.95 (+0.90), IGT: 16.39 (+0.20), REGN: 393.72 (+0.92), PII: 150.86 (+2.30), BABA: 98.60 (-0.13)
FDA approves vaccine to block meningitis strain
By MATTHEW PERRONE - AP - Wed Oct 29, 3:50PM CDT
WASHINGTON (AP) — Federal health regulators have approved the first vaccine to block a strain of bacteria that has caused sometimes deadly outbreaks of meningitis in college dormitories.
PFE: 29.95 (+0.11)
Pfizer Rises 1.38% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Wed Oct 29, 3:38PM CDT
Pfizer (NYSE
FE) traded in a range yesterday that spanned from a low of $29.04 to a high of $29.63. Yesterday, the shares gained 1.4%, which took the trading range above the 3-day high of $29.30 on volume of 27.1 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
PFE: 29.95 (+0.11)
SmarTrend Watching for Potential Pullback in Shares of Pfizer After 1.38% Gain
Comtex SmarTrend(R) - Wed Oct 29, 3:38PM CDT
Pfizer (NYSE FE) traded in a range yesterday that spanned from a low of $29.04 to a high of $29.63. Yesterday, the shares gained 1.4%, which took the trading range above the 3-day high of $29.30 on volume of 27.1 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
PFE: 29.95 (+0.11)
Pfizer Receives FDA Accelerated Approval for TRUMENBA(R) (Meningococcal Group B Vaccine) for the Prevention of Invasive Meningococcal B Disease in Adolescents and Young Adults
Business Wire - Wed Oct 29, 1:44PM CDT
Pfizer Inc. (NYSE FE) announced today that the U.S. Food and Drug Administration (FDA) has granted accelerated approval of TRUMENBA(R) (meningococcal group B vaccine) for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B in individuals 10 through 25 years of age. Approval of TRUMENBA is based on demonstration of immune response, as measured by serum bactericidal activity against four serogroup B strains representative of prevalent strains in the United States. The effectiveness of TRUMENBA against diverse serogroup B strains has not been confirmed. As part of the accelerated approval process, Pfizer will complete its ongoing studies to confirm the effectiveness of TRUMENBA against diverse serogroup B strains.
PFE: 29.95 (+0.11)
3 Dividend Stocks Better Than Pfizer, Inc.
Todd Campbell, The Motley Fool - Motley Fool - Sat Nov 01, 10:17AM CDT
Pfizer reported third-quarter earnings this week that were generally underwhelming. The drugmaker announced that its sales sagged 2.2% to $12.36 billion and its adjusted EPS fell similarly by 2% year over year in the quarter. Pfizer's...
NVO: 45.18 (-1.03), PFE: 29.95 (+0.11), AMGN: 162.18 (+0.60), NVS: 92.69 (+0.74)
Most active New York Stock Exchange-traded stocks
AP - Fri Oct 31, 5:04PM CDT
NEW YORK (AP) — A look at New York Stock Exchange 10 most-active stocks at the close of trading:
CCI: 78.12 (-5.12), F: 14.09 (+0.14), GE: 25.81 (+0.14), ABX.TO: 13.38 (-0.37), K.TO: 2.41 (-0.35), ABX: 11.87 (-0.42), C: 53.53 (+0.38), PFE: 29.95 (+0.11), BAC: 17.16 (+0.13), YRI.TO: 4.49 (-0.50), KGC: 2.15 (-0.34), S: 5.93 (-0.07), AUY: 3.98 (-0.48)
Final Glance: Pharmaceuticals companies
AP - Fri Oct 31, 5:04PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading:
JNJ: 107.78 (+0.74), BAX: 70.14 (+0.08), PFE: 29.95 (+0.11), BMY: 58.19 (-0.79)
Will Zoetis (ZTS) Pull a Surprise this Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 31, 4:10PM CDT
Zoetis Inc. (ZTS) is scheduled to report third-quarter 2014 results before the opening bell on Nov 4.
ZTS: 37.16 (-0.16), ACT: 242.74 (-0.47), PFE: 29.95 (+0.11), HSP: 53.70 (-0.54)
Midday Glance: Pharmaceuticals companies
AP - Fri Oct 31, 1:49PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:
JNJ: 107.78 (+0.74), BAX: 70.14 (+0.08), PFE: 29.95 (+0.11), BMY: 58.19 (-0.79)
Early Glance: Pharmaceuticals companies
AP - Fri Oct 31, 11:28AM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 10 a.m.:
JNJ: 107.78 (+0.74), BAX: 70.14 (+0.08), PFE: 29.95 (+0.11), BMY: 58.19 (-0.79)
Dow 30 Stock Roundup: DuPont, Merck, Pfizer Beat Estimates - Analyst Blog
Swarup Gupta - Zacks Investment Research - Fri Oct 31, 10:41AM CDT
The Dow experienced gains every day of the week, but for Wednesday, boosted by positive economic data and bullish earnings results.
MMM: 153.77 (+1.67), GS: 189.99 (+3.02), V: 241.43 (+4.78), IBM: 164.40 (+0.05), MRK: 57.94 (+0.63), PFE: 29.95 (+0.11), DD: 69.15 (+1.49), CAT: 101.41 (+1.25), PG: 87.27 (+0.33), MSFT: 46.95 (+0.90)
Stock Market News for October 31, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Fri Oct 31, 9:10AM CDT
Benchmarks ended in the green zone on Thursday, banking on encouraging third quarter GDP numbers and upbeat quarterly results
JNJ: 107.78 (+0.74), NEE: 100.22 (+0.31), V: 241.43 (+4.78), GILD: 112.00 (-2.22), DUK: 82.15 (-0.14), EXC: 36.59 (-0.11), MRK: 57.94 (+0.63), PFE: 29.95 (+0.11), ABBV: 63.46 (+2.28), DTE: 82.16 (+0.17), SO: 46.36 (-0.09), MA: 83.75 (+0.62)
Pfizer's Trumenba Gains Accelerated Approval in the U.S. - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Oct 30, 5:04PM CDT
Pfizer Inc.'s (PFE) Trumenba received accelerated FDA approval for prevention of invasive disease caused by Neisseria meningitidis serogroup B in people aged 10 - 25 years.
MNK: 92.18 (-0.65), ACT: 242.74 (-0.47), PFE: 29.95 (+0.11), MYL: 53.55 (+1.18)
'Mad Money' Lightning Round: Stay Away From Applied Materials
at The Street - Thu Oct 30, 5:00AM CDT
Cramer prefers Isis Pharmaceuticals to Pfizer and Kinder Morgan to El Paso Pipeline Partners.
KMI: 38.70 (+0.16), EPB: 40.65 (+0.10), ISIS: 46.06 (+0.18), PFE: 29.95 (+0.11), AMAT: 22.09 (+0.75), INVN: 16.21 (+0.54), IGT: 16.39 (+0.20), REGN: 393.72 (+0.92), CVRR: 24.24 (-0.10), CELG: 107.09 (+0.15)
Jim Cramer's 'Mad Money' Recap: Where to Find Bargains Created by the Fed
at The Street - Wed Oct 29, 7:12PM CDT
With the Federal Reserve finally ending its bond buying, there are many stocks that are ready to be bought, not sold, on any Fed-induced weakness, Cramer says.
KMI: 38.70 (+0.16), ETN: 68.39 (+1.62), FB: 74.99 (+0.88), PFE: 29.95 (+0.11), INVN: 16.21 (+0.54), WDC: 98.37 (+3.18), HPQ: 35.88 (+0.56), CVRR: 24.24 (-0.10), CELG: 107.09 (+0.15), EPB: 40.65 (+0.10), ISIS: 46.06 (+0.18), IBM: 164.40 (+0.05), AMAT: 22.09 (+0.75), GOOGL: 567.87 (+7.60), TWTR: 41.47 (-0.33), MSFT: 46.95 (+0.90), IGT: 16.39 (+0.20), REGN: 393.72 (+0.92), PII: 150.86 (+2.30), BABA: 98.60 (-0.13)
FDA approves vaccine to block meningitis strain
By MATTHEW PERRONE - AP - Wed Oct 29, 3:50PM CDT
WASHINGTON (AP) — Federal health regulators have approved the first vaccine to block a strain of bacteria that has caused sometimes deadly outbreaks of meningitis in college dormitories.
PFE: 29.95 (+0.11)
Pfizer Rises 1.38% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Wed Oct 29, 3:38PM CDT
Pfizer (NYSE
FE) traded in a range yesterday that spanned from a low of $29.04 to a high of $29.63. Yesterday, the shares gained 1.4%, which took the trading range above the 3-day high of $29.30 on volume of 27.1 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious. PFE: 29.95 (+0.11)
SmarTrend Watching for Potential Pullback in Shares of Pfizer After 1.38% Gain
Comtex SmarTrend(R) - Wed Oct 29, 3:38PM CDT
Pfizer (NYSE
FE) traded in a range yesterday that spanned from a low of $29.04 to a high of $29.63. Yesterday, the shares gained 1.4%, which took the trading range above the 3-day high of $29.30 on volume of 27.1 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious. PFE: 29.95 (+0.11)
Pfizer Receives FDA Accelerated Approval for TRUMENBA(R) (Meningococcal Group B Vaccine) for the Prevention of Invasive Meningococcal B Disease in Adolescents and Young Adults
Business Wire - Wed Oct 29, 1:44PM CDT
Pfizer Inc. (NYSE
FE) announced today that the U.S. Food and Drug Administration (FDA) has granted accelerated approval of TRUMENBA(R) (meningococcal group B vaccine) for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B in individuals 10 through 25 years of age. Approval of TRUMENBA is based on demonstration of immune response, as measured by serum bactericidal activity against four serogroup B strains representative of prevalent strains in the United States. The effectiveness of TRUMENBA against diverse serogroup B strains has not been confirmed. As part of the accelerated approval process, Pfizer will complete its ongoing studies to confirm the effectiveness of TRUMENBA against diverse serogroup B strains. PFE: 29.95 (+0.11)
